Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > SO OATS GUESS WHO IS UP FOR THE NEW BOARD
View:
Post by Hopeforthebest on Jun 29, 2024 11:15am

SO OATS GUESS WHO IS UP FOR THE NEW BOARD

Curious on what your thoughts are of gagnon now that he is running to be on the Board once again, Didn't this lowlife promise to retire if you supported him 1 more time? now that you did and your support is no longer required this (cannot say without being banned) is doing the exact opposite.

Unfortunely the misguided trust you place in this (again cannot say) person has cost investors millions while he and his buddies continual to collect millions. You had the opportunity to put an end to his (again cannot say) taking millions without any accountability but failed not only yourself, your investment partners and the thousands who had stocks in Ceapro.

I hope the word gets out that what gagnon really is (i believe the investment already knows, just look at the stock price), a man who word cannot be trusted.

Anybody who has the opportunity to vote please do and vote NO as the above is just a prime example what we have to look forward too if gagnon and his cohorts are in it for 1 thing, money money money while sthe stock once again reaches no lows.
Comment by Ciao on Jun 29, 2024 12:46pm
Shareholders should vote NO to the resolution for changing the company's name. New investors need to be warned of the historical performance and mismanagement of the company. I can assure you that once the name change occurs, there will be an equity raise.
Comment by Hopeforthebest on Jun 29, 2024 1:18pm
Ciao, i would say that investors and the pharma community is aware that gagnon's word is not to be trusted. The inability of the savour, NoShowRonnie, to interest investors or the direction the stock is going is an indication that gagnon's and his actions are already well known. To make ife easy just vote NO to everything these 2 charlatons are pushing. 
Comment by Ciao on Jun 29, 2024 1:23pm
Yes, vote NO to everything.  We don't know what OATS frame of mind was when he concluded that those minor concessions would be better than to halt the merger and to eventually remove Gagnon from the CEO's seat. 
Comment by tigerpro on Jun 30, 2024 12:44am
It is amazing that the CEO can stay in the board and do whatever he wants for such a long time.  Nobody voted him out. I can only say that some shareholders deserve the current results and loss.  That is sad...
Comment by lscfa on Jun 30, 2024 7:05pm
Gagnon got plenty of no votes at the last AGMs of CZO and AEZS. Let's get rid of him this time.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities